Resistance to tyrosine kinase inhibitor

To describe the clinical and subclinical features of lung cancer patients with EGFR mutations before TKIs therapy and in the relapsed period. To identify the T790M mutation and MET amplification in patients with lung cancer and EGFR-TKIs resistance and the relationship with clinical and subclinical features.

29p cothumenhmong6 17-07-2020 12 2   Download